Protalix Biotherapeutics (PLX) Given “Buy” Rating at HC Wainwright

Protalix Biotherapeutics (NYSEAMERICAN:PLX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday. They presently have a $5.00 price target on the stock.

Several other research firms also recently weighed in on PLX. Zacks Investment Research raised shares of Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub downgraded shares of Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 2nd.

Protalix Biotherapeutics (PLX) traded down $0.01 during trading on Thursday, reaching $0.68. 352,801 shares of the company traded hands, compared to its average volume of 1,141,155. Protalix Biotherapeutics has a 12-month low of $0.48 and a 12-month high of $1.51. The stock has a market cap of $325.24, a P/E ratio of -0.34 and a beta of 0.97.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.04). The company had revenue of $7.53 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter last year, the business earned ($0.07) earnings per share.

An institutional investor recently bought a new position in Protalix Biotherapeutics stock. OxFORD Asset Management LLP purchased a new stake in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 687,796 shares of the company’s stock, valued at approximately $576,000. OxFORD Asset Management LLP owned 0.54% of Protalix Biotherapeutics as of its most recent filing with the SEC.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/01/protalix-biotherapeutics-plx-given-buy-rating-at-hc-wainwright.html.

Protalix Biotherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply